en بیوشیمی Biochemistry پژوهشي Research <div style="text-align: justify;"><span style="font-size:12pt"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt">Background and Aims:</span></b><span style="font-size:10.0pt"> <em><span style="background:white"><span style="letter-spacing:.05pt">Atorvastatin may alter glycemic traits and lipid profiles. </span></span></em>This study aimed to evaluate the effects of atorvastatin on biochemical variables in patients with type 2 diabetes and pre-diabetes (borderline diabetes).</span></span></span><br> <span style="font-size:12pt"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt">Materials and Methods:</span></b><span style="font-size:10.0pt"> This study included 80 individuals divided into<br> five groups. Patients with type 2 diabetes mellitus and pre-diabetes used atorvastatin 20 mg/day for three months. After three months, variables<br> such as serum fasting blood glucose (FBS), cholesterol, triglyceride, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol<br> (HDL-C), and glycosylated hemoglobin (HbA1c) levels were measured to assess the status of diabetes and pre-diabetes condition. Linear regression was applied to determine the association between atorvastatin uses and alters of biochemical variables levels.</span></span></span><br> <span style="font-size:12pt"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt">Results:</span></b><span style="font-size:10.0pt"> The serum FBS and HbA1c levels in patients with diabetes and pre-diabetes who use atorvastatin were significantly lower than in patients with diabetes and pre-diabetes who did not use atorvastatin (p=0.001). Serum cholesterol and LDL-C levels decreased in diabetic and pre-diabetic patients who used atorvastatin in comparison with diabetic and pre-diabetic patients who did not use atorvastatin (p=0.001). In patients with pre-diabetes, the use of atorvastatin slightly increased serum HDL-C levels. However, in patients with diabetes, the use of atorvastatin slightly decreased serum HDL-C level (p= 0.001). Diabetic and pre-diabetic patients who use atorvastatin significantly decreased serum triglyceride levels (p=0.016), while in diabetic and pre-diabetic patients, using atorvastatin slightly increased the serum insulin level (p= 0.003).</span></span></span><br> <b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Conclusions:</span></span></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""> Atorvastatin using alters fat and sugar indices in diabetic and pre-diabetic patients.</span></span></div> Atorvastatin, Diabetes, HDL-C, LDL-C, Pre-diabetes 198 208 http://ijml.ssu.ac.ir/browse.php?a_code=A-10-350-3&slc_lang=en&sid=1 Ali Nosrati Andevari علی نصرتی nosrati.ali70@gmail.com 0000-0002-8699-4688 No Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran soheila Moein سهیلا معین soheila-9@yahoo.com 0000-0001-8465-3604 No Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 2 Department of Biochemistry, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Durdi Qujeq دردی قوجق dqujeq@gmail.com 0000-0003-1344-9344 Yes Cellular and Molecular Biology Research Center (CMBRC), Health Research Institute, Babol University of Medical Sciences, Babol, IRAN مر کز تحقیقات سلولی و مولکولی دانشگاه علوم پزشکی بابل Zoleika zmoazezi ذلیخا معززی zmoazezi@yahoo.com 0000-0001-5915-9460 No Department of Internal Medicine, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran Karimollah Hajian-Tilaki کریم اله حاجیان drhajian@yahoo.com 0000-0001-6830-1916 No Department of Statistics and Epidemiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran